Table 4. Price of medicines by countries where tested, by number of months of income needed to pay for a course of treatment or a year of treatment for chronic conditions by monthly minimum wage (MMW), monthly income per capita (MIPC)) in US$.
(All MNW and MIPC figures above 3 months have been rounded)a.
| Argentina | Brazilb | Chile | Colombia | Mexico | Peru | |
|---|---|---|---|---|---|---|
| GDP in purchasing power parity (PPP) (World Bank, 2014) | 12.568c | 15,110 | 21,980 | 12,743 | 16,287 | 11,438 |
| NME and Dosage | ||||||
| Aflibercept, 8 injections per year | ||||||
| Price | 30,410 | 15,259 | 10,882 | 10,122 | NI | -- |
| MMW | 58 | 46 | 28 | 33 | NI | -- |
| MIPC | 25 | 16 | 8 | 16 | NI | -- |
| Apixaban, Two, 5 mg pills per day (730 per year). | ||||||
| Price | 1,858 | 1,259 | 1,714 | 1,294 | 1,536 | R, NA |
| MMW | 3.5 | 3.8 | 5 | 4 | 14 | -- |
| MIPC | 1.5 | 1.5 | 0.9 | 2 | 2 | -- |
| Azilsartan medoxonil, 80 mg once a day (365 pills per year). | ||||||
| Price | R, NA | -- | R, NA | -- | 1,026 | R, NA |
| MMW | -- | -- | -- | -- | 10 | -- |
| MIPC | -- | -- | -- | -- | 1.2 | -- |
| Belatacept, 10 mg per Kg per treatment. A person weighing up to 50 Kg needs 2 vials per treatment, and 16 treatments per year. | ||||||
| Price | 42,508 | 3,293 | R, NA | -- | R, NA | -- |
| MMW | 81 | 10 | -- | -- | -- | -- |
| MIPC | 35 | 4 | -- | -- | -- | -- |
| Belimumab, 10 mg/Kg at 2-week interval for the first 3 doses and 4 weeks intervals thereafter. For a total of 15 treatments per year. | ||||||
| Price | N I | 20,995 | 7,725 | R, NA | NI | NR, GSK says it is A |
| MMW | -- | 64 | 20 | -- | -- | -- |
| MIPC | -- | 23 | 6 | -- | -- | -- |
| Crizotinib | -- | R, NA | -- | -- | -- | |
| Indacaterol, 75 μg once a day | ||||||
| Price | ||||||
| 150μg | 798 | -- | 435 | 878 | -- | NI |
| 300μg | 844 | -- | 809 | NA | -- | NI |
| MMW | ||||||
| 150μg | 1.5 | -- | 1.1 | 3. | -- | -- |
| 300μg | 1.6 | -- | 2.5 | NA | -- | -- |
| MIPC | ||||||
| 150 μg | 0.6 | -- | 0.5 | 1.3 | -- | -- |
| 300μg | 0.7 | -- | 0.6 | NA | -- | -- |
| Ipilimumab, 3mg/kg IV infusion over 90 minutes every 3 weeks for 4 cycles | ||||||
| Price | 175,697 | 100,189 | 96,212 | -- | -- | NI |
| MMW | 336 | 305 | 249 | -- | -- | NI |
| MIPC | 143 | 107 | 74 | -- | -- | NI |
| Linagliptin, 5 mg once a day | ||||||
| Price | 1,012 | -- | -- | -- | 1,120 | NI |
| MMW | 1.9 | -- | -- | -- | 10 | NI |
| MIPC | 0.8 | -- | -- | -- | 1.3 | NI |
| Pasireotide, 600 or 900μg twice a day | ||||||
| Price | ||||||
| 600μg | 143,309 | R, A? | -- | -- | 88,061 | -- |
| 900μg | 164,799 | -- | -- | -- | 99,413 | -- |
| MMW | ||||||
| 600μg | 274 | -- | -- | -- | 793 | -- |
| 900μg | 315 | -- | -- | -- | 896 | -- |
| MIPC | ||||||
| 600μg | 117 | -- | -- | -- | 113 | -- |
| 900μg | 134 | -- | -- | -- | 116 | -- |
| Pertuzumab, Initial dose 840mg as a 60-minute IV infusion, followed every 3 weeks thereafter by 420mg as a 30 to 60 minute IV infusion | ||||||
| Price | -- | 58,979 | -- | -- | 73.713 | R, A? |
| MMW | -- | 179 | -- | -- | 644 | -- |
| MIPC | -- | 75 | -- | -- | 85 | -- |
| Regorafenib, 4 tablets a day, 21 days of 28-day cycle | ||||||
| Price | 19,584 | NI | -- | -- | -- | -- |
| MMW | 37 | -- | -- | -- | -- | -- |
| MIPC | 16 | -- | -- | -- | -- | -- |
| Rilpivirine, For HIV-1 infection in adults who have never taken HIV therapy | R, A? | NR, NA | NR, A? | -- | R, A? | -- |
| Rivaroxavan, 10 mg once a day (Knee = 12 days; Hip = 35 days) | ||||||
| Price Knee | 162 | 42.6 | 55.6 | 170 | 59 | 60 |
| MMW | 0.3 | 0.1 | 0.1 | 0.6 | 1 | 0.2 |
| MIPC | 0.1 | 0.1 | 0.04 | 0.3 | 0.1 | 0.1 |
| Price Hip | 476 | 124 | 162 | 496 | 171 | 160 |
| MMW | 0.9 | 0.4 | 0.4 | 1.6 | 2 | 1 |
| MIPC | 0.4 | 0.1 | 0.1 | 0.8 | 0.2 | 0.3 |
| Roflumilast, One tablet 500 mcg per day | ||||||
| Price | -- | 993 | -- | -- | -- | -- |
| MMW | -- | 3 | -- | -- | -- | -- |
| MIPC | -- | 1 | -- | -- | -- | -- |
| Taliglucerasa alfa, 60 units/kg IV every 2 weeks, 26 treatments per year | ||||||
| Price | -- | -- | 266,960 | -- | -- | -- |
| MMW | -- | -- | 584 | -- | -- | -- |
| MIPC | -- | -- | 203 | -- | -- | -- |
| Telaprevir, 1125 mg twice a day, for 12 weeks | ||||||
| Price | 52,061 | 44,554 | -- | -- | -- | -- |
| MMW | 99 | 135 | -- | -- | -- | -- |
| MIPC | 42 | 48 | -- | -- | -- | -- |
| Teriflunomide | -- | -- | R, A? | -- | R, A? | -- |
| Ticagrelor, 90 mg twice a day | ||||||
| Price | 2,681 | 1,407 | -- | -- | 1,879 | -- |
| MMW | 5 | 4 | -- | -- | 17 | -- |
| MIPC | 2 | 1.5 | -- | -- | 1.8 | -- |
| Tofacitinib, 5mgr twice a day | ||||||
| Price | 45,252 | NR, NA | N I | 13,504 | 18,308 | R, A? |
| MMW | 86.5 | -- | -- | 44 | 165 | -- |
| MIPC | 37 | -- | -- | 21 | 22 | -- |
| Vandetanib, 300 mg once a day | ||||||
| Price | 213,618 | 117,848 | -- | -- | NR, A? | -- |
| MMW | 408 | 358 | -- | -- | -- | -- |
| MIPC | 174 | 126 | -- | -- | -- | -- |
Information regarding the methodology to determine the MMW and MIPC can be found in Homedes and Ugalde.10 In Ecuador there was information only for Indacaterol, and to simplify the table we have not included the information and is available from corresponding author.
a For cells with no information, no clinical trials were conducted in the country or the product is not available. A = Available, A? = could not confirm if the product was available in the specific country, NA = Not Available; NI = No information available: R = registered: NR = Not registered
bIn Brazil, Anvisa publishes a list of maximum prices for the consumer that does not include taxes. The tax rate varies by state from 0–19%. We have included the maximum tax rate to the Anvisa prices.
c All GDP data are reported in PPP which are in US dollars and based on Atlas methodology used by the IMF and the World Bank. The Argentina GDP per capita is based on data officially reported by the National Statistics and Censuses Institute of Argentina that do not estimate the PPP. The International Monetary Fund (IMF) has called on Argentina to adopt measures to address the quality of official GDP and consumer price index data. More information available in http://data.worldbank.org/indicator/NY.GDP.PCAP.PP.KD